Pituitary disorders:
Indications for Cabergoline:
Hyperprolactinemic disorders, either idiopathic or due to pituitary tumors.
Adult Dosage:
Initially 0.25mg twice weekly. Dose may be increased at 4-week intervals by 0.25mg twice weekly. Max: 1mg twice weekly.
Children Dosage:
Not established.
Cabergoline Contraindications:
Uncontrolled hypertension. Sensitivity to ergot alkaloids.
Cabergoline Warnings/Precautions:
Not for pregnancy-induced hypertension or postpartum lactation inhibition or suppression. Respiratory or cardiac disease due to fibrosis. Psychiatric disorders (eg, impulse control/compulsive behaviors, pathological gambling, increased libido). Hepatic impairment. Pregnancy. Nursing mothers: not recommended.
Cabergoline Classification:
Dopamine agonist.
Cabergoline Interactions:
Concurrent dopamine D2 antagonists (eg, phenothiazines, butyrophenones, thioxanthines, metoclopramide): not recommended. Hypotension may be potentiated by antihypertensives.
Adverse Reactions:
GI upset, dizziness, fatigue, postural hypotension, nervousness, breast pain, dysmenorrhea, vision abnormalities; rare: fibrosis, valvulopathy.
Note:
Formerly known under the brand name Dostinex.
How Supplied:
Contact supplier.
